Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, September 24, 2009
Wed, September 23, 2009
Naked Short Web Site Announces GNBT, COIN, DLII Have Been Removed From Threshold Lists Today
September 23, 2009 /M2 PRESSWIRE/ BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold lists. Generex Biotechnology (NASDAQ: GNBT), Converted Organics (NASDAQ: COIN) and Dixie Lee International (OTC: DLII). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Generex Biotechnology Corporation (NASDAQ: GNBT), a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. The company primarily focuses on its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly-owned subsidiary, Antigen Express, Inc. (Antigen), the company focuses on immunomedicines incorporating proprietary vaccine formulations. BUCCAL DELIVERY TECHNOLOGY AND PRODUCTS Buccal Insulin Product a" Generex Oral-Lyn The companya�s primary pharmaceutical product, Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its proprietary hand-held aerosol spray applicator known as RapidMist for the treatment of Type-1 and Type-2 diabetes. The company has received regulatory approval in Ecuador and India for the commercial marketing and sale of Generex Oral-lyn. In March 2008, it initiated Phase III clinical trials for this product in the U.S. with the first patient screening for such trials at a clinical study site in Texas. Buccal Glucose and Energy Products - Glucose RapidSpray, BaBOOM! Energy Spray and GlucoBreak The company, using its proprietary buccal delivery technology, has developed various formulations of glucose sprays that are available over-the-counter. It offers Glucose RapidSpray, which uses its proprietary RapidMist platform technology to provide an alternative for people who require or want additional glucose in their diet and delivers a low-calorie glucose formulation directly into the mouth. Glucose RapidSpray is available in the United States and Canada through various retail chains, wholesalers and online. It is also available wholesale in the Middle East through its Generex MENA office in Dubai. The companya�s line of over-the-counter products using its proprietary RapidSpray delivery device also include GlucoBreak, a fat-free glucose spray that is marketed as an aid for dieters and can be used between meals as part of a daily diet routine, during exercise and before bedtime; and BaBOOM! Energy Spray is an instant energy spray designed to improve energy levels for sports, work, study, travel and overall fatigue. Its primary ingredients include glucose, caffeine, ginseng and Vitamins B and C. BaBOOM! Energy Spray and GlucoBreak are being considered for commercial sale in various national and regional retailers and drug store chains in the United States and Canada. Glucose RapidSpray is being marketed in the Middle East through the Generex MENA office in Dubai and in South Africa and six neighboring countries through the Master Distributor Agreement with Adcock Ingram Limited and Adcock Ingram Healthcare (Pty), Ltd. Metformin Gum Product/Strategic Alliance The company has established a collaborative alliance with Fertin Pharma A/S, a Danish manufacturer of medicinal chewing gum, for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity. Metformin is a generic drug used to regulate blood glucose levels. IMMUNOMEDICINE TECHNOLOGY AND PRODUCTS The companya�s wholly-owned subsidiary, Antigen, is developing proprietary vaccine formulations based upon two platform technologies, the Ii-Key hybrid peptides and Ii-Suppression. These technologies are applicable for either antigen-specific immune stimulation or suppression, depending upon the dosing and formulation of its products. Using active stimulation, the company is focusing on major diseases, such as breast and prostate cancer, H5N1 avian influenza and HIV. Autoimmune disease, such as diabetes, multiple sclerosis and allergic asthma are the focus of its antigen-specific immune suppression work. Antigena�s immunotherapeutic vaccine AE37 is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The trial is being conducted with the United States Military Cancer Institute's (USMCI) Clinical Trials Group. The company has entered into an agreement with the Euroclinic, a private center in Athens, Greece, to commence clinical t rials with the same compound as an immunotherapeutic vaccine for prostate cancer. In March 2007, Antigen entered into an agreement with Beijing Daopei Hospital in Beijing, China to conduct clinical trials using Antigena�s pioneering technology for RNA interference (RNAi) stimulation of the immune response against patientsa� immune cells. Marketing and Distribution Generex Oral-Lyn: The company has entered into licensing and distribution agreement with various multinational distributors to assist the company with the process of gaining regulatory approval for the registration, marketing, distribution, and sale of Generex Oral-lyn in countries throughout the world, including: Leosons General Trading Company/Generex MENA Office - 15 Middle Eastern countries; Shreya Life Sciences Pvt., Ltd. - India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and Myanmar; Adcock Ingram Limited and Adcock Ingram Healthcare (Pty), Ltd. - South Africa, Lesotho, Swaziland, Botswana, Namibia, Mozambique, and Zimbabwe; E&V Alca Distribution Corp. - Albania, Montenegro, and the Kosovo; Medrey S.A.L. and Benta S.A.L. a" Lebanon; SciGen, Ltd. - China, Hong Kong, Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam; and Dong Sung Pharm. Co. Ltd. a" South Korea. Over-the-Counter Products: The company has entered into distribution agreements with various pharmaceutical wholesalers, including Cardinal Health; AmerisourceBergen Corporation; Amerimark Direct; DIK Drug Co.; H.D. Smith Wholesale Drug; Kinray, Inc.; Smith Drug Company; Value Drug Company; RDC; Kohl & Frisch Limited; UniPharm Wholesale Drugs, Ltd; and McKesson Canada, for the distribution of Glucose RapidSpray in retail stores in the United States and Canada. Glucose RapidSpray is sold in the United States and Canada through various retail chains, including: Rite Aid; Butler Drug Store; Rexall PharmaPlus; Fruth Pharmacy; Loblaws Companies, Ltd.; Hy-Vee, Inc.; Kerr Drug, Inc.; Kinney Drug, Inc.; Medicine Shop; Meijer; ShopKo; Weiss Markets, Inc.; Aurora Pharmacy; and Shoppers Drug Mart. Glucose RapidSpray is also available for sale on the Internet through Amazon.com, Walgreens.com, AmericanDiabetesWholesale.com and DiabeticExpress.com, as well as in independent drugstores throughout North America. Significant Events The company and Pevion Biotech, Ltd. have signed an agreement to work together to develop next-generation vaccines and immunotherapeutic products. On May 14, 2009, Generex Biotechnology Corp., together with Benta S.A.L., the company's importation, marketing, distribution and sales sub-licensee in Lebanon announced the launch of commercial retail sales of Generex Oral-lyn in Lebanon. The product has been approved for importation and commercial marketing and sale in Lebanon by the Ministry of Public Health, and would be marketed and sold for the treatment of patients with Type-1 and Type-2 diabetes in Lebanon. On September 2, 2009, Generex Biotechnology Corp. announced that it has incorporated SIA 'Generex Biotechnology BALTIC' in the European Union as a wholly-owned subsidiary of Generex. The purpose of the subsidiary is to harness and develop the local marketplace in the Baltic region and surrounding for the company's flagship product Generex Oral-lyn and its metabolic disease pipeline products, including MetControl, Glucose RapidSpray and the company's other confectionary products as well as its immunotherapeutic vaccine platform particularly in the influenza application. Competition The companya�s competitors include MannKind Corporation; CPEX Pharmaceuticals, Inc.; Abbott Laboratories; Emisphere Technologies, Inc.; Novo Nordisk A/S; Nastech Pharmaceutical Company, Inc.; Cephalon, Inc.; Advaxis, Inc.; Micromet, Inc.; Sanofi Pasteur, Inc.; Dendreon Corporation; Cell Genesys, Inc.; Pharmexa-Epimmune, Inc.; and Cel-Sci Corporation. History Generex Biotechnology Corporation was founded in 1983. There is no longer a failure to deliver in shares of GNBT
Converted Organics Inc. (NASDAQ: COIN) engages in the manufacture, sale, and distribution of soil amendment products combining disease suppression and nutrition characteristics. In addition to its sales in the agribusiness market, the company sells and distributes its products in the turf management and retail markets. The company operates two processing facilities that use food waste as raw material, including Woodbridge facility, which processes solid waste and is producing both liquid and dry fertilizer and soil enhancement products; and Gonzales facility. The company has license to sell products from its Woodbridge facility to the Eastern Seaboard states, including Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania, Delaware, Maryland, Virginia, District of Columbia, North Carolina, South Carolina, Georgia, and Florida. History Converted Organics Inc. was founded in 2003. There is no longer a failure to deliver in shares of COIN.
Dixie Lee International Industries, Inc. (OTC: DLII) operates as a franchisor and trademark holder of Dixie Lee Restaurants, located primarily in eastern Canada. The company operates approximately 100 restaurants. It also intends to offer their franchises in the United States under the aDixie Lee Dinera� banner and offer master franchise developments in Europe, the Middle East, and Asian markets, including mainland China. The company was founded in 1964 and is based in Napanee, Canada. There is no longer a failure to deliver in shares of DLII.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.com/squeezetrigger.pdf . The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Occasionally companies mentioned in this report pay a $995.00 monthly data fee to Buyins.net for one month of research data. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO / www.BUYINS.net / (800) 715-9999 / tom@buyins.net
- WOPRAI
- support@woprai.com
- www.woprai.com